Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a targeted drug plus donor immune cells fight back against relapsed leukemia?

NCT ID NCT03374332

Completed ⭐️ CURE ⭐️ Sponsor: Brown University Source: ClinicalTrials.gov ↗

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This trial is for adults with relapsed or refractory acute myeloid leukemia (AML) who have no standard curative options. Researchers are testing whether giving the drug gemtuzumab ozogamicin followed by an infusion of donor white blood cells can stimulate the immune system to attack the leukemia. The study first checks safety in a small group, then may enroll more participants to see if the combination leads to remission.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
gemtuzumab ozogamicin followed by donor leukocyte infusions
What this could lead to
If it works, this could point toward a treatment option for people with relapsed AML who have no other curative choices.
What could go wrong
This is an early-phase trial testing safety and dosing, so it may not lead to a proven treatment. Risks include toxicities from the drug or the donor cell infusion.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia Disease Progression Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

  • Rhode Island Hospital

    Providence, Rhode Island, 02903, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.